Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...
H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on BPMC stock, giving a Buy rating today. Andrew Fein’s rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback